Evidence map›Paper›PMID 33824267›Full record

ArticleCell death & disease2021

MLL5 improves ATRA driven differentiation and promotes xenotransplant engraftment in acute promyelocytic leukemia model.

Diego A Pereira-Martins, Isabel Weinhäuser, Juan Luiz Coelho-Silva, Pedro L França-Neto, Luciana Y Almeida, Thiago M Bianco, Cleide L Silva, Rafael F França, Fabiola Traina, Eduardo M Rego and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. CanPharmaceuticals (Basel, Switzerland) · 2024
    Review
  7. Article
  8. HighCancers · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Diego A Pereira-Martins *Department of Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Isabel Weinhäuser *Department of Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Juan Luiz Coelho-SilvaCenter for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.ORCID 0000-0001-8384-6551
Pedro L França-NetoDepartment of Genetics, Federal University of Pernambuco, Recife, Brazil.
Luciana Y AlmeidaCenter for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
Thiago M BiancoCenter for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.ORCID 0000-0001-5326-0162
Cleide L SilvaCenter for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
Rafael F FrançaDepartment of Virology, Aggeu Magalhaes Institute/Oswaldo Cruz Foundation, Recife, Brazil.ORCID 0000-0002-1846-6007
Fabiola TrainaCenter for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.ORCID 0000-0003-4258-289X
Eduardo M RegoCenter for Cell-Based Therapy, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
Jan Jacob SchuringaDepartment of Hematology, Cancer Research Centre Groningen, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0001-8452-8555
Antonio R Lucena-AraujoDepartment of Genetics, Federal University of Pernambuco, Recife, Brazil. araujoarl@gmail.com.ORCID 0000-0003-1694-8958
Universidade de São Paulo · BRUniversity Medical Center Groningen · NLUniversidade Federal de Pernambuco · BRFundação Oswaldo Cruz · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the mixed lineage leukemia 5 (MLL5) gene has prognostic implications in acute promyelocyte leukemia (APL), the underlying mechanism remains to be elucidated. Here, we demonstrate the critical role exerted by MLL5 in APL regarding cell proliferation and resistance to drug-induced apoptosis, through mtROS regulation. Additionally, MLL5 overexpression increased the responsiveness of APL leukemic cells to all-trans retinoic acid (ATRA)-induced differentiation, via regulation of the epigenetic modifiers SETD7 and LSD1. In silico analysis indicated that APL blasts with MLL5

Indexed as

Antineoplastic AgentsApoptosisCell DifferentiationCell Line, TumorCell ProliferationDNA-Binding ProteinsHeterograftsHistone DemethylasesHumansLeukemia, Promyelocytic, AcuteTranscription FactorsAntineoplastic AgentsDNA-Binding ProteinsHistone DemethylasesKMT2E protein, humanTranscription Factors

Identifiers

PMID33824267
PMCPMC8024355
OpenAlexW3150391789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.